CUE (Cue Biopharma) Inventory Turnover: 0.00 (As of Mar. 2026)

What is Cue Biopharma Inventory Turnover?

Cue Biopharma CUE -0.28% 59 Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.36 (Possible Value Trap). The stock has 3 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Cue Biopharma's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil. Cue Biopharma's Average Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cue Biopharma's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

Cue Biopharma (NAS:CUE) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cue Biopharma's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cue Biopharma's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	0	/	5.686
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Cue Biopharma Inventory Turnover Related Terms

Cue Biopharma Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Inventory Turnover can be seen below:

Cue Biopharma Inventory Turnover Chart

Cue Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

0.00

Cue Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

59GF Score

Cue Biopharma Inc CUE

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cue Biopharma Inventory Turnover Calculation

Cue Biopharma's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Cue Biopharma's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.00 mean?

Cue Biopharma (CUE) has a Inventory Turnover of 0.00 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Cue Biopharma and its competitors.

Is Cue Biopharma's Inventory Turnover too high?

Cue Biopharma's current Inventory Turnover is 0.00. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Cue Biopharma's Inventory Turnover compare to ALPS and AARD?

Cue Biopharma's Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cue Biopharma stock overvalued right now?

Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.36, compared to a current price of $28.33 — trading 54.6% below its estimated fair value. The current Inventory Turnover is 0.00. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $28.33 is trading 54.6% below its estimated GF Value™ of $62.36. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

Inventory Turnover: 0.00
GF Value™: $62.36 vs. price of $28.33 (54.6% below fair value)
GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies ALPS AARD KLRS VANI CBUS ALDX PTHS CGTX ONCY BDTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 1UC0:Germany

Address 40 Guest Street, Boston, MA, USA, 02135

Website https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

59GF Score

Get the complete analysis for CUE

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.33

Price

$62.36

GF Value

View CUE Analysis

See Inventory Turnover data for all stocks →